首页> 外文期刊>Asian Journal of Pharmaceutical and Clinical Research >SERUM IMMUNOGLOBULIN AND COMPLEMENT LEVELS IN PATIENTS WITH BREAST CANCER IN IRAQ
【24h】

SERUM IMMUNOGLOBULIN AND COMPLEMENT LEVELS IN PATIENTS WITH BREAST CANCER IN IRAQ

机译:伊拉克乳腺癌患者的血清免疫球蛋白和补体水平

获取原文
           

摘要

Objective: The objective of this study was to estimate the serum immunoglobulins (IgA, IgM, and IgG) levels, and complements (C3 and C4) level in Iraqi women with breast cancer pre-treatment and post-treatment. Methods: A total number of 100 patients aged 25–47 years were enrolled in this study, including 35 breast cancer treatment patients, 30 treatment patients, and 10 and 25 healthy women benefactor. All samples were collected from August 2016 to February 2017 from Oncology Hospital/Medical city in Baghdad exception of the control group were collected from outside the hospital. Serum levels of IgG, IgA, IgM, C3, and C4 were measured by radial immunodiffusion technique. Results: Serum mean values of IgA, IgG, and C3were significantly higher (p?0.01) in patients pre-treatment than in post-treatment. The level of the serum for patients pre-treatment was significantly higher than post-treatment. Conclusion: The present study showed the increase of serum IgA, IgG, and C3 levels can be considered as biomarker for breast cancer diagnosis pre-treatment and post-treatment.
机译:目的:本研究的目的是评估接受乳腺癌治疗的伊拉克妇女的血清免疫球蛋白(IgA,IgM和IgG)水平以及补体(C3和C4)水平。方法:本研究共纳入100名年龄在25-47岁之间的患者,其中包括35名乳腺癌治疗患者,30名治疗患者以及10和25名健康女性恩人。从2016年8月至2017年2月,所有样本均从巴格达的肿瘤医院/医疗城采集,对照组则从医院外采集。通过放射免疫扩散技术测量血清IgG,IgA,IgM,C3和C4水平。结果:治疗前患者的IgA,IgG和C3血清均值明显高于治疗后(p?0.01)。治疗前患者的血清水平显着高于治疗后。结论:本研究表明血清IgA,IgG和C3水平的升高可被认为是乳腺癌诊断治疗前后的生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号